CHA Vaccine Research Institute (KOSDAQ:261780)
South Korea · Delayed Price · Currency is KRW 2,635.00
0.00 (0.00%)
At close: Feb 19, 2026
CHA Vaccine Research Institute Company Description
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases.
Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster.
The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer vaccine, as well as anti-cancer immunotherapy drugs.
Cha Vaccine Research Institute Co., Ltd. was incorporated in 2000 and is headquartered in Seongnam-si, South Korea.
CHA Vaccine Research Institute
| Country | South Korea |
| Founded | 2000 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Jungsun Yum |
Contact Details
Address: 560 Dunchon-daero Seongnam-si, 13230 South Korea | |
| Phone | 82 31 737 8208 |
| Website | chavaccine.com |
Stock Details
| Ticker Symbol | 261780 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jungsun Yum | Chief Executive Officer |